Significant progresses have been made in patients’ enrolment in the DEEP-2 study (multicentre, randomized, open label, controlled trial aimed at comparing the efficacy of deferiprone and deferasirox in paediatric patients).
So far, 8 Italian centres have already started the patients’ enrollment: recently the Azienda Ospedaliera di Padova (AOSP) has completed the enrolment of its eighth patient, providing a huge contribution for the success of the DEEP-2 study, while the ASL Ospedale Regionale per le Microcitemie of Cagliari and the Faculty of Medicine – University of Bari have started the recruitment with 2 and 1 patients respectively. Furthermore on the 31st of March, 2015 Centro di Studi della Microcitemia of Cosenza has included its first patient in the study.
Finally, 3 of 10 patients, enrolled by the Azienda Ospedaliera di Rilievo Nazionale “Antonio Cardarelli” in Naples, have already completed the 14th visit (V14), which corresponds to the 11th of 12 months under the chelation therapy foreseen by the study protocol.
These results represent another step forward for the success of the DEEP-2 study, demonstrating a growing interest of the Italian centres in the study and its objectives.